bioAffinity’s CyPath® Lung uses flow cytometry to analyze the cells in a person’s sputum, or phlegm, to find cancer cells that have sloughed off a lung tumor during collection of the sample. To get a sample, a person blows into a simple, non-invasive assist device that acts to break up mucus and help a person cough up the phlegm. The sputum sample is shipped to the laboratory, labeled with CyPath® that includes antibodies that distinguish different cell types and a porphyrin that identifies cancer cells and cancer-associated cells. The sputum sample is analyzed using flow cytometry, a well-established automated platform that quantitates properties of single cells very quickly. An average sputum sample containing about 21 million cells can be profiled cell-by-cell by flow cytometry in less than 20 minutes.
Current screening for lung cancer calls for using low dose computed tomography (LDCT) that finds earlier stage cancer in people at high risk for the disease to significantly increase survival. Screening is an important tool to find early lung cancer and increase survival, but LDCT has a low positive predictive value that can lead to unnecessary invasive procedures. CyPath® Lung will be ordered by physicians for patients who they suspect have lung cancer.
CyPath® Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.
Through its subsidiary, OncoSelect Therapeutics, our Company focuses on expanding its broad platform technology to create targeted therapeutics to fight cancer. In researching porphyrins’ selectivity for cancer, we discovered novel therapies that kill cancer cells without harm to normal cells in vitro. We continue with animal studies to advance our discoveries. Our research also looks to attach cancer-killing drugs to porphyrins, a cancer-selective molecule, that is taken up by tumors in much greater amounts than by non-cancer tissue. OncoSelect Therapeutics will be developing a diverse number of targeted therapeutics in our fight against cancer.